 Dr. Mark McClellan is director of the Duke-Margolis Institute for Health Policy and a former FDA commissioner. Better data will help, but the other big problem is that we don't have a market that really rewards reliability. So the way a lot of these contracts for buying drugs are set up, the hospitals might have or their purchasing organization might have an arrangement with a manufacturer. But if they find a lower price on the market today,